Economic evaluation of Qili Qiangxin capsules for the treatment of chronic heart failure
Evidence-Based Chinese Medicine and Technology Assessment · 2026-03 · 2 (1) · 9570029
DOI: 10.26599/ecmta.2026.9570029 ↗Kurz gefasst
Fachartikel in der Zeitschrift Evidence-Based Chinese Medicine and Technology Assessment, 2026-03. Verfasst von Hua-liang Deng und 20 weiteren Autor:innen. Die Arbeit nennt 23 Literaturangaben.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Introduction
Chronic heart failure (CHF) confers high mortality and heavy economic burden as a critical public health issue. Qili Qiangxin (QLQX) capsules, a traditional Chinese patent medicine, may improve clinical outcomes in CHF patients. This study evaluated the economic value of QLQX capsules for CHF.
Methods
A health economic analysis was performed from the healthcare system perspective. Cost-effectiveness analysis was used for short-term outcomes, and a Markov model-based cost-utility analysis for long-term outcomes. Robustness was tested using one-way and probabilistic sensitivity analyses.
Results
A total of 1555 patients were equally randomized to two groups: QLQX capsules plus standard of care (QLQX group) or standard of care alone (control group). Baseline characteristics were comparable between groups. In the QLQX group, 1-year direct medical costs were ¥9368.08 ($1311.53; 95% confidence interval [CI]: [¥8980.61, ¥9755.55]), versus ¥6402.21 ($896.31; 95% CI: [¥5903.50, ¥6900.91]) in the control group. The higher costs in the QLQX group were primarily driven by medication expenses. Composite endpoint events occurred in 19.00% (95% CI: [17.07%, 21.03%]) of the QLQX group compared with 23.40% (95% CI: [21.34%, 25.61%]) of the control group (P = 0.003). The incremental cost-effectiveness ratio (ICER) was ¥67 406.14 ($9436.86). Over a 15-year time horizon, the QLQX group incurred total costs of ¥57 096 ($7993.44) and achieved 5.46 QALYs, whereas the control group incurred ¥34 016 ($4762.24) and achieved 5.07 QALYs, resulting in an ICER of ¥58 946 per QALY ($8252.44/QALY). This value is below China’s 2023 per capita gross domestic product threshold (¥89 358; $12 510.12), suggesting that QLQX capsule is highly cost-effective. Sensitivity analyses further confirmed the robustness of these findings.
Conclusion
QLQX capsules were associated with higher short-term costs but greater efficacy than standard care, and long-term modeling supports their high cost-effectiveness.
Zitieren
APA
Deng, H., Yu, S., Wang, F., Liu, C., Liu, X., Wang, X., Xu, W., Wang, J., Zheng, G., Zhou, J., Xie, X., He, Y., Zhang, K., Gao, D., Cui, J., Sun, G., Li, D., Xie, X., Cheang, I., …, & Jia, Z. (2026). Economic evaluation of Qili Qiangxin capsules for the treatment of chronic heart failure. Evidence-Based Chinese Medicine and Technology Assessment, 2(1), 9570029. https://doi.org/10.26599/ecmta.2026.9570029
Vancouver
Deng H, Yu S, Wang F, Liu C, Liu X, Wang X, et al. Economic evaluation of Qili Qiangxin capsules for the treatment of chronic heart failure. Evidence-Based Chinese Medicine and Technology Assessment. 2026;2(1):9570029. doi:10.26599/ecmta.2026.9570029
BibTeX
@article{Deng2026,
author = {Deng, Hua-liang and Yu, Si-jun and Wang, Fan and Liu, Chun-hui and Liu, Xia and Wang, Xiao-ye and Xu, Wen-ling and Wang, Jia-xin and Zheng, Guan-zhong and Zhou, Jian-hua and Xie, Xing-ze and He, Yong and Zhang, Kai-yan and Gao, Di-fei and Cui, Jia-yu and Sun, Gui-fang and Li, De-cai and Xie, Xing-hong and Cheang, Iokfai and Ding, Ning-xin and Jia, Zhen-hua},
title = {Economic evaluation of Qili Qiangxin capsules for the treatment of chronic heart failure},
journal = {Evidence-Based Chinese Medicine and Technology Assessment},
year = {2026},
volume = {2},
number = {1},
pages = {9570029},
doi = {10.26599/ecmta.2026.9570029}
}
EUVIMED